Identification
- Summary
Oxacillin is a penicillin antibiotic used to treat a number of susceptible bacterial infections.
- Generic Name
- Oxacillin
- DrugBank Accession Number
- DB00713
- Background
An antibiotic similar to flucloxacillin used in resistant staphylococci infections.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Oxacillin (DB00713)
- Weight
- Average: 401.436
Monoisotopic: 401.104541423 - Chemical Formula
- C19H19N3O5S
- Synonyms
- (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- (5-methyl-3-phenyl-4-isoxazolyl)penicillin
- 5-methyl-3-phenyl-4-isoxazolyl-penicillin
- 6β-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid
- Ossacillina
- Oxacilina
- Oxacillin
- Oxacilline
- Oxacillinum
- Oxazocillin
- Oxazocilline
- External IDs
- AB 1400
- BRL 1400
- P 12
- SQ 16423
Pharmacology
- Indication
Used in the treatment of resistant staphylococci infections.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
- Mechanism of action
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor.
Target Actions Organism APenicillin-binding protein 3 inhibitorStreptococcus pneumoniae APenicillin-binding protein 2a inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 1A inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 2B inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 1b inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 1A inhibitorClostridium perfringens (strain 13 / Type A) USolute carrier family 15 member 1 Not Available Humans UPenicillin-binding protein 2 Not Available Staphylococcus aureus USolute carrier family 15 member 2 Not Available Humans UBeta-lactamase Toho-1 substrateEscherichia coli - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
94.2 +/- 2.1% (binds to serum protein, mainly albumin)
- Metabolism
- Not Available
- Route of elimination
Oxacillin Sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion.
- Half-life
20 to 30 minutes
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Oxacillin may decrease the excretion rate of Abacavir which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Oxacillin which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Oxacillin which could result in a higher serum level. Acenocoumarol Oxacillin may increase the anticoagulant activities of Acenocoumarol. Acetaminophen Acetaminophen may decrease the excretion rate of Oxacillin which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Oxacillin which could result in a higher serum level. Aclidinium Oxacillin may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Oxacillin may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Oxacillin which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Oxacillin sodium 4TWD2995UP 1173-88-2 VDUVBBMAXXHEQP-SLINCCQESA-M Oxacillin sodium monohydrate G0V6C994Q5 7240-38-2 ZVIYWUUZWWBNMB-VICXVTCVSA-M - International/Other Brands
- Bactocill (Baxter Healthcare) / Biocilina (Biogalenic) / Bristopen (Bristol-Myers Squibb) / Dicloxal Ox (Magma) / InfectoStaph (Infectopharm) / Ocillina (CCPC) / Oxacil (Unimed) / Oxacilina (Billi Farmacêutica) / Oxacilinã (Antibiotice) / Oxagram (Medicef) / Oxal (Endure Medical) / Oxamicin (Ronava) / Oxapen (Biolab) / Oxipen (Behrens) / Panadox (Shijiazhuang) / Penstapho (Bristol-Myers Squibb) / Prostafilina (Bristol-Myers Squibb) / Prostaphlin (Bristol-Myers Squibb) / Stafcil (Aurobindo) / Staficilin-N (Bristol-Myers Squibb) / Wydox (YSS)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Oxacillin Injection, solution 2 g/50mL Intravenous Baxter Healthcare Corporation 1989-10-26 Not applicable US 
Oxacillin Injection, solution 1 g/50mL Intravenous Baxter Healthcare Corporation 1989-10-26 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Oxacillin Injection, powder, for solution 1 g/1g Intramuscular; Intravenous Renaissance Ssa, Llc 2018-06-01 Not applicable US Oxacillin Injection, powder, for solution 1 g/1 Intravenous Sandoz Inc 1986-12-23 2018-11-30 US Oxacillin Injection, powder, for solution 2 g/1 Intramuscular; Intravenous Sandoz 1976-01-06 Not applicable US Oxacillin Injection, powder, for solution 2 g/2g Intramuscular; Intravenous Piramal Critical Care Inc 2018-06-01 2022-08-01 US Oxacillin Injection, powder, for solution 2 g/1 Intramuscular; Intravenous Sandoz 1976-01-06 Not applicable US Oxacillin Injection, powder, for solution 2 g/20mL Intramuscular; Intravenous Fresenius Kabi USA, LLC 2020-11-01 Not applicable US Oxacillin Powder, for solution 2 g/1 Intramuscular; Intravenous Hospira, Inc. 2015-12-11 2015-12-11 US Oxacillin Injection, powder, for solution 1 g/20mL Intramuscular; Intravenous Wockhardt USA LLC. 2017-07-31 Not applicable US Oxacillin Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Eugia US LLC 2013-01-18 Not applicable US Oxacillin Injection, powder, for solution 2 g/1 Intravenous Sandoz Inc 1986-12-23 2018-11-30 US
Categories
- ATC Codes
- J01CR50 — Combinations of penicillins
- J01CR — Combinations of penicillins, incl. beta-lactamase inhibitors
- J01C — BETA-LACTAM ANTIBACTERIALS, PENICILLINS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Amides
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Beta-Lactam Antibacterials
- Beta-Lactamase Resistant Penicillins
- beta-Lactams
- Drugs that are Mainly Renally Excreted
- Heterocyclic Compounds, Fused-Ring
- Lactams
- Penicillins
- Sulfur Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Dipeptides
- Alternative Parents
- Penicillins / N-acyl-alpha amino acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Thiazolidines / Heteroaromatic compounds / Isoxazoles / Secondary carboxylic acid amides / Azetidines / Thiohemiaminal derivatives show 10 more
- Substituents
- Alpha-amino acid or derivatives / Alpha-dipeptide / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Azole / Benzenoid / Beta-lactam / Carbonyl group / Carboxamide group show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- penicillin (CHEBI:7809)
- Affected organisms
- Enteric bacteria and other eubacteria
- Staphylococcus aureus
Chemical Identifiers
- UNII
- UH95VD7V76
- CAS number
- 66-79-5
- InChI Key
- UWYHMGVUTGAWSP-JKIFEVAISA-N
- InChI
- InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1
- IUPAC Name
- (2S,5R,6R)-3,3-dimethyl-6-(5-methyl-3-phenyl-1,2-oxazole-4-amido)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- SMILES
- [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014851
- KEGG Drug
- D08307
- KEGG Compound
- C07334
- PubChem Compound
- 6196
- PubChem Substance
- 46505710
- ChemSpider
- 5961
- BindingDB
- 50350483
- 7773
- ChEBI
- 7809
- ChEMBL
- CHEMBL819
- ZINC
- ZINC000003875439
- Therapeutic Targets Database
- DAP000440
- PharmGKB
- PA450725
- PDBe Ligand
- 105
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Oxacillin
- MSDS
- Download (38 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Community Acquired Pneumonia (CAP) 1 4 Completed Treatment Skin Diseases, Infectious 1 4 Enrolling by Invitation Treatment Endocarditis 1 4 Not Yet Recruiting Treatment Bone and Joint Infections / Endovascular Infection / Gastrointestinal Tract Infections / Genitourinary tract infection / Pulmonary Infections / Skin and Soft Tissue Infections (SSTIs) 1 4 Terminated Treatment Complicated Skin and Skin Structure Infection / Impaired Renal Function / S. Aureus Bacteremia 1 3 Completed Treatment Bacteremia / Bacterial Infections / Gram Positive Bacterial Infections 1 3 Completed Treatment Infection 1 3 Terminated Treatment Bacteremia 1 3 Withdrawn Treatment Osteomyelitis 1 2 Active Not Recruiting Treatment Staphylococcal bacteraemia 1
Pharmacoeconomics
- Manufacturers
- Glaxosmithkline
- Apothecon inc div bristol myers squibb
- Teva pharmaceuticals usa inc
- Baxter healthcare corp
- Apothecon sub bristol myers squibb co
- Elkins sinn div ah robins co inc
- Istituto biochimico italiano spa
- Marsam pharmaceuticals llc
- Sandoz inc
- Watson laboratories inc
- Packagers
- Baxter International Inc.
- Carlisle Laboratories Inc.
- Dispensing Solutions
- Mead Johnson and Co.
- Physicians Total Care Inc.
- Sandoz
- SC Antibiotice SA
- Teva Pharmaceutical Industries Ltd.
- Dosage Forms
Form Route Strength Injection, powder, for solution Intramuscular; Intravenous 1 g Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g Injection, powder, for solution Intravenous 1 g Injection, powder, for solution Parenteral 1 g Injection, powder, for solution Intramuscular; Intravenous 1 g/20mL Injection, powder, for solution Intramuscular; Intravenous 1 g/1g Injection, powder, for solution Intramuscular; Intravenous 1 g/1 Injection, powder, for solution Intramuscular; Intravenous 2 g/20mL Injection, powder, for solution Intramuscular; Intravenous 2 g/2g Injection, powder, for solution Intramuscular; Intravenous 2 g/1 Injection, powder, for solution Intravenous 1 g/1 Injection, powder, for solution Intravenous 10 g/10g Injection, powder, for solution Intravenous 10 g/100mL Injection, powder, for solution Intravenous 2 g/1 Injection, solution Intravenous 1 g/50mL Injection, solution Intravenous 2 g/50mL Powder, for solution Intramuscular; Intravenous 1 g/1 Powder, for solution Intramuscular; Intravenous 2 g/1 Powder, for solution Intravenous 10 g/100mL Capsule 250 MG Injection, powder, for solution Intramuscular 1 g/5ml Injection, powder, for solution Intramuscular 500 mg Injection, powder, for solution Intravenous 1 g/5ml Injection, powder, for solution Parenteral 1 G/5ML Injection, powder, for solution Parenteral 250 MG/2ML Injection, powder, for solution Parenteral 500 MG - Prices
Unit description Cost Unit Oxacillin 10 gm vial 118.01USD each Oxacillin 2 gm vial 24.08USD each Oxacillin 1 gm vial 12.41USD each Oxacillin 2 gm/ 50 ml inj 0.62USD ml Oxacillin 1 gm/ 50 ml inj 0.43USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 188 °C PhysProp water solubility 13.9 mg/L Not Available logP 2.38 HANSCH,C ET AL. (1995) pKa 2.72 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.0862 mg/mL ALOGPS logP 2.05 ALOGPS logP 1.7 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 3.75 Chemaxon pKa (Strongest Basic) -0.12 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 112.74 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 101.83 m3·mol-1 Chemaxon Polarizability 39.61 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8002 Blood Brain Barrier - 0.9923 Caco-2 permeable + 0.7059 P-glycoprotein substrate Non-substrate 0.6161 P-glycoprotein inhibitor I Non-inhibitor 0.867 P-glycoprotein inhibitor II Non-inhibitor 0.922 Renal organic cation transporter Non-inhibitor 0.9669 CYP450 2C9 substrate Non-substrate 0.8181 CYP450 2D6 substrate Non-substrate 0.8807 CYP450 3A4 substrate Substrate 0.5347 CYP450 1A2 substrate Inhibitor 0.5746 CYP450 2C9 inhibitor Non-inhibitor 0.8725 CYP450 2D6 inhibitor Non-inhibitor 0.9111 CYP450 2C19 inhibitor Non-inhibitor 0.8665 CYP450 3A4 inhibitor Non-inhibitor 0.665 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9564 Ames test Non AMES toxic 0.7304 Carcinogenicity Non-carcinogens 0.5273 Biodegradation Not ready biodegradable 0.9759 Rat acute toxicity 1.6583 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9997 hERG inhibition (predictor II) Non-inhibitor 0.8773
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Streptococcus pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Not Available
- Gene Name
- pbp3
- Uniprot ID
- Q75Y35
- Uniprot Name
- Penicillin-binding protein 3
- Molecular Weight
- 45209.84 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring acyl groups
- Specific Function
- Not Available
- Gene Name
- pbp2a
- Uniprot ID
- Q8DNB6
- Uniprot Name
- Penicillin-binding protein 2a
- Molecular Weight
- 80797.94 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Penicillin binding
- Specific Function
- Cell wall formation.
- Gene Name
- pbpA
- Uniprot ID
- Q8DR59
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 79700.9 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- Penicillin binding
- Gene Name
- penA
- Uniprot ID
- P0A3M6
- Uniprot Name
- Penicillin-binding protein 2B
- Molecular Weight
- 73872.305 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring acyl groups
- Specific Function
- Not Available
- Gene Name
- pbp1b
- Uniprot ID
- Q7CRA4
- Uniprot Name
- Penicillin-binding protein 1b
- Molecular Weight
- 89479.92 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Clostridium perfringens (strain 13 / Type A)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring glycosyl groups
- Specific Function
- Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
- Gene Name
- pbpA
- Uniprot ID
- Q8XJ01
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 75176.35 Da
References
- Williamson R: Resistance of Clostridium perfringens to beta-lactam antibiotics mediated by a decreased affinity of a single essential penicillin-binding protein. J Gen Microbiol. 1983 Aug;129(8):2339-42. doi: 10.1099/00221287-129-8-2339. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
- Kind
- Protein
- Organism
- Staphylococcus aureus
- Pharmacological action
- Unknown
- General Function
- Penicillin binding
- Specific Function
- Not Available
- Gene Name
- mecA
- Uniprot ID
- D6R448
- Uniprot Name
- Penicillin-binding protein 2
- Molecular Weight
- 10694.04 Da
References
- Chung M, Antignac A, Kim C, Tomasz A: Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother. 2008 Aug;52(8):2709-17. doi: 10.1128/AAC.00266-08. Epub 2008 May 27. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Peptide:proton symporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
- Gene Name
- SLC15A2
- Uniprot ID
- Q16348
- Uniprot Name
- Solute carrier family 15 member 2
- Molecular Weight
- 81782.77 Da
References
- Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G: Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorg Med Chem. 2011 Aug 1;19(15):4544-51. doi: 10.1016/j.bmc.2011.06.027. Epub 2011 Jun 16. [Article]
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Beta-lactamase activity
- Specific Function
- Has strong cefotaxime-hydrolyzing activity.
- Gene Name
- bla
- Uniprot ID
- Q47066
- Uniprot Name
- Beta-lactamase Toho-1
- Molecular Weight
- 31446.6 Da
References
- Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H: Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother. 1995 Oct;39(10):2269-75. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Peptide:proton symporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
- Gene Name
- SLC15A2
- Uniprot ID
- Q16348
- Uniprot Name
- Solute carrier family 15 member 2
- Molecular Weight
- 81782.77 Da
References
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
Drug created at June 13, 2005 13:24 / Updated at December 01, 2023 07:39